MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii
Ključne besede
Povzetek
Opis
This is a retrospective cohort with collection of tissues samples (FFPE or frozen), including female patients >18-year-old treated in French between 2009 and 2016 for a thyroid carcinoma on struma ovarii. Clinical data and tissues will be centralized for assessment. One of the endpoint is the description of the population (such as baseline clinical and pathologist characteristics, first treatment, survival, treatment relapse) ; the other endpoint is the comparison between the genomic profile of the tumor tissues obtained in NGS and those of the thyroid carcinomas obtained from the TCGA.
Datumi
Nazadnje preverjeno: | 06/30/2019 |
Prvič predloženo: | 07/03/2019 |
Predviden vpis oddan: | 08/08/2019 |
Prvič objavljeno: | 08/11/2019 |
Zadnja posodobitev oddana: | 08/08/2019 |
Zadnja posodobitev objavljena: | 08/11/2019 |
Dejanski datum začetka študija: | 08/31/2019 |
Predvideni datum primarnega zaključka: | 11/30/2019 |
Predvideni datum zaključka študije: | 04/30/2020 |
Stanje ali bolezen
Intervencija / zdravljenje
Other: Retrospective cohort
Faza
Skupine rok
Roka | Intervencija / zdravljenje |
---|---|
Retrospective cohort Tissue samples | Other: Retrospective cohort Next generation sequencing (NGS) |
Merila upravičenosti
Starost, primerna za študij | 18 Years Za 18 Years |
Spol, upravičen do študija | Female |
Metoda vzorčenja | Non-Probability Sample |
Sprejema zdrave prostovoljce | Da |
Merila | Inclusion Criteria: - Alive patients, - Age > 18 years, - Treatment in France for a TCSO, proven by an histologic diagnosis and registered in the " rare malignant gynecologic tumors " network. Exclusion Criteria: - Patient lost to follow up. |
Izid
Primarni izidni ukrepi
1. Treatment description [Between first treatment and last follow up, assessed up to 100 months]
Ukrepi sekundarnega rezultata
1. Age of diagnostic (years) [At baseline (first treatment)]
2. Comorbidities [At baseline (first treatment)]
3. FIGO stage [At baseline (first treatment)]
4. Histologic type [At baseline (first treatment)]
5. Survival [Between first treatment and last follow up, assessed up to 100 months]
6. Prognostic factors [At baseline (first treatment)]
7. Focus on genes of interest in thyroid carcinomas [At baseline (first treatment)]
8. Focus on ALK translocation [At baseline (first treatment)]
9. Focus on TERT mutation [At baseline (first treatment)]
10. Comparison of the tissue samples genomic profile with the Thyroid carcinoma TCGA genomic profile [At baseline (first treatment)]
11. Comparison between TCSO tissue samples genomic profile and benign SO tissue samples genomic profile [At baseline (first treatment)]